Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies von de Tute, Ruth M

Volltext

Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at r... von Cohen, Oliver C., Counsell, Nicholas, Rabin, Neil, Popat, Rakesh, Owen, Roger G., Popova, Bilyana, Schofield, Oliver, Clifton‐Hadley, Laura, Lyons‐Lewis, Janet, Rawstron, Andy, Spence, Christopher, Tute, Ruth M., Hughes, Derralynn, Moore, Sally, Smith, Paul, Yong, Kwee L.

Volltext

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome von Poulter, James A., Collins, Jason C., Cargo, Catherine, De Tute, Ruth M., Evans, Paul, Ospina Cardona, Daniela, Bowen, David T., Cunnington, Joanna R., Baguley, Elaine, Quinn, Mark, Green, Michael, McGonagle, Dennis, Beck, David B., Werner, Achim, Savic, Sinisa

Volltext

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study von RAWSTRON, Andy C, CHILD, J. Anthony, ROSS, Fiona M, COOK, Gordon, JACKSON, Graham H, MORGAN, Gareth J, OWEN, Roger G, DE TUTE, Ruth M, DAVIES, Faith E, GREGORY, Walter M, BELL, Sue E, SZUBERT, Alexander J, NAVARRO-COY, Nuria, DRAYSON, Mark T, FEYLER, Sylvia

Volltext

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction von Rawstron, Andy C., Gregory, Walter M., de Tute, Ruth M., Davies, Faith E., Bell, Sue E., Drayson, Mark T., Cook, Gordon, Jackson, Graham H., Morgan, Gareth J., Child, J. Anthony, Owen, Roger G.

Volltext

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis von Hill, Quentin A., Rawstron, Andy C., de Tute, Ruth M., Owen, Roger G.

Volltext

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim... von Jackson, Graham H, Pawlyn, Charlotte, Cairns, David A, de Tute, Ruth M, Hockaday, Anna, Collett, Corinne, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Drayson, Mark T, Gregory, Walter M, Kaiser, Martin F, Owen, Roger G, Davies, Faith E, Morgan, Gareth J

Volltext

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: res... von Yong, Kwee L., Hinsley, Samantha, Auner, Holger W., Bygrave, Ceri, Kaiser, Martin F., Ramasamy, Karthik, De Tute, Ruth M., Sherratt, Debbie, Flanagan, Louise, Garg, Mamta, Hawkins, Stephen, Williams, Catherine, Cavenagh, Jamie, Rabin, Neil K., Croft, James, Morgan, Gareth, Davies, Faith, Owen, Roger G., Brown, Sarah R.

Volltext

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen von de Tute, Ruth M, Rawstron, Andy C, Gregory, Walter M, Child, J Anthony, Davies, Faith E, Bell, Sue E, Cook, Gordon, Szubert, Alexander J, Drayson, Mark T, Jackson, Graham H, Morgan, Gareth J, Owen, Roger G

Volltext

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma von Kaiser, Martin F, Hall, Andrew, Walker, Katrina, Sherborne, Amy, De Tute, Ruth M, Newnham, Nicola, Roberts, Sadie, Ingleson, Emma, Bowles, Kristian, Garg, Mamta, Lokare, Anand, Messiou, Christina, Houlston, Richard S, Jackson, Graham, Cook, Gordon, Pratt, Guy, Owen, Roger G, Drayson, Mark T, Brown, Sarah R, Jenner, Matthew W

Volltext

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk von de Tute, Ruth M, Pawlyn, Charlotte, Cairns, David A, Davies, Faith E, Menzies, Tom, Rawstron, Andy, Jones, John R, Hockaday, Anna, Henderson, Rowena, Cook, Gordon, Drayson, Mark T, Jenner, Matthew W, Kaiser, Martin F, Gregory, Walter M, Morgan, Gareth J, Jackson, Graham H, Owen, Roger G

Volltext

Defining IgM multiple myeloma von Owen, Roger G, Feyler, Sylvia, O'Connor, Sheila JM, Bond, Lee R, de Tute, Ruth M, Rawstron, Andy C

Volltext

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial von de Tute, Ruth M., Cook, Gordon, Cairns, David A., Brown, Julia M., Cavenagh, Jamie, Ashcroft, A. John, Snowden, John A., Yong, Kwee, Tholouli, Eleni, Jenner, Matthew, Hockaday, Anna, Drayson, Mark T., Morris, Treen C. M., Rawstron, Andy C., Owen, Roger G.

Volltext

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diag... von Yong, Kwee, Wilson, William, de Tute, Ruth M, Camilleri, Marquita, Ramasamy, Karthik, Streetly, Matthew, Sive, Jonathan, Bygrave, Ceri A, Benjamin, Reuben, Chapman, Michael, Chavda, Selina J, Phillips, Elizabeth H, del Mar Cuadrado, Maria, Pang, Gavin, Jenner, Richard, Dadaga, Tushhar, Kamora, Sumaiya, Cavenagh, James, Clifton-Hadley, Laura, Owen, Roger G, Popat, Rakesh

Volltext

Translocation t(14;16) in IgM multiple myeloma von Owen, Roger G., O’Connor, Sheila J. M., Bond, Lee R, de Tute, Ruth M, Rawstron, Andy C.

Volltext

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diag... von Rawstron, Andy C., de Tute, Ruth M., Haughton, J., Owen, Roger G.

Volltext

Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells von de Tute, Ruth M, Rawstron, Andy C, Owen, Roger G

Volltext

Reply to M. Roschewski et al von Rawstron, Andy C, Child, J Anthony, de Tute, Ruth M, Davies, Faith E, Gregory, Walter M, Bell, Sue E, Szubert, Alexander J, Navarro Coy, Nuria, Drayson, Mark T, Feyler, Sylvia, Ross, Fiona M, Cook, Gordon, Jackson, Graham H, Morgan, Gareth J, Owen, Roger G

Volltext

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure von Rawstron, Andy C., Hillmen, Peter, Maycock, Shanna, Webster, Nichola, Brock, Kristian, Boucher, Rebecca H., Yates, Francesca, Jarvis, Rebecca, Dalal, Surita, de Tute, Ruth M., Moss, Paul, Macdonald, Donald, Patten, Piers, Fegan, Christopher, Pettitt, Andrew, Fox, Christopher P., Bloor, Adrian, Sheehy, Oonagh, Hillmen, Peter

Volltext

Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia von de Tute, Ruth M, Shingles, Jane, Rawstron, Andy C., Owen, Roger G

Volltext